Secondary analysis
Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial
- Prespecified analysis of the DELIVER randomised trial
Authors' conclusion
Patients with longer-duration HF were older, had more comorbidities and symptoms, and had higher rates of worsening HF and death. The benefits of dapagliflozin were consistent across HF duration.
Study context
- Population
- Patients with heart failure (HF) with mildly reduced or preserved EF
- Participants
- 1,160 / 842 / 995 / 1,569 / 1,692
- Comparison
- Dapagliflozin vs placebo, by HF duration
- ≤6 monthsn = 1,160
- >6 to 12 monthsn = 842
- >1 to 2 yearsn = 995
- >2 to 5 yearsn = 1,569
- >5 yearsn = 1,692
- Primary endpoint
- Composite of:
- Worsening HF
- CV death
Primary result
As reported in the abstract
Worsening HF or CV death, dapagliflozin vs placebo by HF duration
Dapagliflozin vs PlaceboHazard ratio (95% CI)
≤6 months
0.67(0.50–0.91)
>6 to 12 months
0.78(0.55–1.12)
>1 to 2 years
0.81(0.60–1.09)
>2 to 5 years
0.97(0.77–1.22)
>5 years
0.78(0.64–0.96)
- NNT, HF >5 years vs ≤6 months
- 24 vs 32
Further findings
Other outcomes by HF duration
- Similar trends (higher rates with longer HF duration)
Original publication
Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial. Circulation. Published 6 March 2023. doi:10.1161/circulationaha.122.062918
Summarised from the published abstract; every number is checked against it